Communique from the Annual General Meeting of Scandion Oncology A/S

On May 27th, 2020, the Annual General Meeting of Scandion Oncology A/S (”Scandion Oncology” or the “Company”) was held. Below follows a summary of the established decisions. All decisions were taken with the required majority.

The Board of Directors report on the Company’s business in the past year

The general meeting took note of the Board of Directors report on the Company’s activities in 2019.

Presentation of the revised annual report for 2019 for approval

The general meeting unanimously adopted the audited annual report for 2019.

Decision to transfer the deficit for next year

The general meeting decided to transfer the deficit to the next year.

Election of members to the Board of Directors

The general meeting decided to elect Bo Rode Hansen as new Board member and to re-elect Peter Høngård Andersen, Jørgen Vilhelm Løvenørn Bardenfleth, Carl Arne Krister Borreback, Thomas Feldthus, and Christian Vinding Thomsen to the Board of Directors until the next Annual General Meeting.

Appointment of auditor

The general meeting decided that the Company’s current auditor, Deloitte is re-elected until the next Annual General Meeting.

Authorization for the Board of Directors to make one or more capital increases

The general meeting decided to authorize the Board of Directors to decide, at one or more occasions, a capital increase pursuant to section 155 of the Danish Companies Act by offering the Company's shares to the public at the Spotlight Stock Market. 

Authorization for the Board of Directors to issue warrants

The Board of Directors proposed that the proposal was not transacted at the general meeting but instead is transacted at a later general meeting in the Company.

Voluntary arrangement for employee representation in the Company

The general meeting decided to adopt a voluntary arrangement for employee representation in the Company.

For further information regarding Scandion Oncology, please contact:

Nils Brünner, CEO

Phone: +45 26 14 47 08

E-mail: nb@scandiononcology.com

Scandion Oncology A/S is a biotechnology company that addresses one of the greatest challenges in modern oncology – the effective treatment of cancer which contains chemotherapy-resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro-studies SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company’s leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now in clinical phase II trials with its lead compound, SCO-101, in patients with chemotherapy-resistant colorectal cancer. In addition to SCO-101 the Company has two other drug candidates, SCO-201 and SCO-301. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018.

Om os

Scandion Oncology A/S has a unique mission: to develop drugs that specifically target drug resistance mechanisms with the aim to extend survival of cancer patients and at the same time improve quality of life of these patients.The business idea is that Scandion Oncology A/S will develop SCO-101 and SCO-201 as add- on medication to treat chemotherapy resistant cancer. SCO-101 is ready for phase II trial and SCO-201 is in preclinical development. After having succesfully completed a Proof of Concept phase II study, Scandion Oncology will outlicense to or seek partnership with big pharma in order to bring the drugs to registration and thereby commercialization.

Abonner

Dokumenter og links